Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.
Nicholas Richardson, DO, MPH
Advertisement
vice president of clinical development, Precision for Medicine, and former FDA deputy director for the Division of Hematologic Malignancies.
Articles by Nicholas Richardson, DO, MPH
The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies, says Nick Richardson, DO, MPH.
Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5